Literature DB >> 34655414

Comparative Therapeutic Potential of Cardioactive Glycosides in Doxorubicin Model of Heart Failure.

Raquel da Silva Ferreira1, Paula Bretas Ullmann Fernandes2, Jéssica Pereira Oliveira da Cruz2, Françoise Louanne Araújo Silva2, Marthin Raboch Lempek2, Gioavanni Naves Canta3, Júlio César Cambraia Veado2, Matheus Matioli Mantovani4, Ana Flávia Machado Botelho5, Marília Martins Melo2.   

Abstract

In the present study, we investigated the cardioactive glycosides oleandrin and ouabain, and compared them to digoxin in a model of cardiotoxicity induced by doxorubicin. Adult rats were distributed into four experimental groups. Each group was challenged with a single intraperitoneal application of doxorubicin at a dose of 12 mg/kg. Then, they were treated with saline solution and the glycosides oleandrin, ouabain, and digoxin at a dose of 50 µg/kg, for 7 days. They underwent echocardiography, electrocardiography, hematologic, biochemical tests, and microscopic evaluation of the heart. All animals presented congestive heart failure, which was verified by a reduction in the ejection fraction. Oleandrin and digoxin were able to significantly reduce (p < 0.05) the eccentric remodeling caused by doxorubicin. Oleandrin and digoxin were significantly lower (p < 0.05) than the control group in maintaining systolic volume and left ventricular volume in diastole. Other parameters evaluated did not show significant statistical differences. All animals showed an increase in erythrocyte count, and an increase in the duration of the QRS complex on the ECG and myocardial necrosis at the histopathological analysis. It is concluded that the glycosides oleandrin, ouabain, and digoxin in the used dosage do not present therapeutic potential for the treatment of congestive heart failure caused by doxorubicin.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardenolides; Cardiac remodeling; Digitalis; Inotropism

Mesh:

Substances:

Year:  2021        PMID: 34655414     DOI: 10.1007/s12012-021-09702-w

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  35 in total

1.  Identification and characterization of a ouabain-like compound from human plasma.

Authors:  J M Hamlyn; M P Blaustein; S Bova; D W DuCharme; D W Harris; F Mandel; W R Mathews; J H Ludens
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

2.  [Digoxin in reduced heart failure and sinus rhythm. When should it be indicated in 2018?]

Authors:  Francesc Formiga; Albert Ariza
Journal:  Rev Esp Geriatr Gerontol       Date:  2018-03-26

3.  Global Public Health Burden of Heart Failure.

Authors:  Gianluigi Savarese; Lars H Lund
Journal:  Card Fail Rev       Date:  2017-04

Review 4.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

Review 5.  A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential.

Authors:  Ana Flávia M Botelho; Felipe Pierezan; Benito Soto-Blanco; Marília Martins Melo
Journal:  Toxicon       Date:  2018-12-04       Impact factor: 3.033

6.  Anatomopathological study of cardiomyopathy induced by doxorubicin in rats.

Authors:  José Carlos Dorsa Vieira Pontes; Jandir Ferreira Gomes Júnior; Guilherme Viotto Rodrigues da Silva; Ricardo Adala Benfatti; Amaury Edgardo Mont'serrat Avila Souza Dias; João Jackson Duarte; Neimar Gardenal; Maçanori Odashiro; Carlos Henrique Marques dos Santos
Journal:  Acta Cir Bras       Date:  2010-04       Impact factor: 1.388

Review 7.  Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

Authors:  Peter A Henriksen
Journal:  Heart       Date:  2017-12-07       Impact factor: 5.994

Review 8.  Endogenous ouabain in cardiovascular function and disease.

Authors:  Paolo Manunta; Mara Ferrandi; Giuseppe Bianchi; John M Hamlyn
Journal:  J Hypertens       Date:  2009-01       Impact factor: 4.844

9.  Comparative Cardiotoxicity of Low Doses of Digoxin, Ouabain, and Oleandrin.

Authors:  Ana F M Botelho; Ana L S Miranda; Thalita G Freitas; Paula F Milani; Tatiane Barreto; Jáder S Cruz; Marília M Melo
Journal:  Cardiovasc Toxicol       Date:  2020-12       Impact factor: 3.231

Review 10.  Decompensated heart failure.

Authors:  Sandrigo Mangini; Philippe Vieira Pires; Fabiana Goulart Marcondes Braga; Fernando Bacal
Journal:  Einstein (Sao Paulo)       Date:  2013 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.